vs
Portillo's Inc.（PTLO）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是Portillo's Inc.的1.1倍（$197.9M vs $185.7M），REPLIGEN CORP净利率更高（6.7% vs 3.4%，领先3.3%），REPLIGEN CORP同比增速更快（13.6% vs 0.6%），REPLIGEN CORP自由现金流更多（$17.6M vs $-9.2M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 5.8%）
Portillo's Inc.是总部位于美国芝加哥地区的休闲快餐连锁品牌，主打芝加哥风味美食，代表菜品包括芝加哥热狗、麦克斯韦街波兰香肠以及意式牛肉三明治。该品牌由迪克·波蒂略于1963年4月9日在伊利诺伊州维拉公园创立，最初门店名为“The Dog House”。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
PTLO vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.1倍
$185.7M
营收增速更快
RGEN
高出13.0%
0.6%
净利率更高
RGEN
高出3.3%
3.4%
自由现金流更多
RGEN
多$26.7M
$-9.2M
两年增速更快
RGEN
近两年复合增速
5.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.7M | $197.9M |
| 净利润 | $6.3M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 5.6% | 9.0% |
| 净利率 | 3.4% | 6.7% |
| 营收同比 | 0.6% | 13.6% |
| 净利润同比 | -49.5% | 143.9% |
| 每股收益（稀释后） | $0.08 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PTLORGEN
| Q4 25 | $185.7M | $197.9M | ||
| Q3 25 | $181.4M | $188.8M | ||
| Q2 25 | $188.5M | $182.4M | ||
| Q1 25 | $176.4M | $169.2M | ||
| Q4 24 | $184.6M | $174.1M | ||
| Q3 24 | $178.3M | $154.9M | ||
| Q2 24 | $181.9M | $154.1M | ||
| Q1 24 | $165.8M | $151.3M |
净利润PTLORGEN
| Q4 25 | $6.3M | $13.3M | ||
| Q3 25 | $1.2M | $14.9M | ||
| Q2 25 | $8.7M | $14.9M | ||
| Q1 25 | $3.3M | $5.8M | ||
| Q4 24 | $12.4M | $-30.3M | ||
| Q3 24 | $7.2M | $-654.0K | ||
| Q2 24 | $6.5M | $3.3M | ||
| Q1 24 | $4.6M | $2.1M |
毛利率PTLORGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率PTLORGEN
| Q4 25 | 5.6% | 9.0% | ||
| Q3 25 | 3.0% | 8.9% | ||
| Q2 25 | 9.3% | 7.6% | ||
| Q1 25 | 5.9% | 3.9% | ||
| Q4 24 | 7.5% | -17.7% | ||
| Q3 24 | 9.0% | -5.1% | ||
| Q2 24 | 10.0% | 1.0% | ||
| Q1 24 | 6.1% | 1.3% |
净利率PTLORGEN
| Q4 25 | 3.4% | 6.7% | ||
| Q3 25 | 0.7% | 7.9% | ||
| Q2 25 | 4.6% | 8.2% | ||
| Q1 25 | 1.9% | 3.4% | ||
| Q4 24 | 6.7% | -17.4% | ||
| Q3 24 | 4.1% | -0.4% | ||
| Q2 24 | 3.6% | 2.2% | ||
| Q1 24 | 2.8% | 1.4% |
每股收益（稀释后）PTLORGEN
| Q4 25 | $0.08 | $0.24 | ||
| Q3 25 | $0.02 | $0.26 | ||
| Q2 25 | $0.12 | $0.26 | ||
| Q1 25 | $0.05 | $0.10 | ||
| Q4 24 | $0.17 | $-0.55 | ||
| Q3 24 | $0.11 | $-0.01 | ||
| Q2 24 | $0.10 | $0.06 | ||
| Q1 24 | $0.08 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $767.6M |
| 总债务越低越好 | $334.2M | $542.2M |
| 股东权益账面价值 | $467.8M | $2.1B |
| 总资产 | $1.6B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.71× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资PTLORGEN
| Q4 25 | — | $767.6M | ||
| Q3 25 | — | $748.7M | ||
| Q2 25 | — | $708.9M | ||
| Q1 25 | — | $697.2M | ||
| Q4 24 | — | $757.4M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $809.1M | ||
| Q1 24 | — | $780.6M |
总债务PTLORGEN
| Q4 25 | $334.2M | $542.2M | ||
| Q3 25 | $322.6M | $537.9M | ||
| Q2 25 | $317.0M | — | ||
| Q1 25 | $319.8M | — | ||
| Q4 24 | $311.7M | $525.6M | ||
| Q3 24 | $302.2M | — | ||
| Q2 24 | $305.1M | — | ||
| Q1 24 | $321.7M | — |
股东权益PTLORGEN
| Q4 25 | $467.8M | $2.1B | ||
| Q3 25 | $459.4M | $2.1B | ||
| Q2 25 | $458.9M | $2.1B | ||
| Q1 25 | $406.9M | $2.0B | ||
| Q4 24 | $401.1M | $2.0B | ||
| Q3 24 | $382.4M | $2.0B | ||
| Q2 24 | $370.2M | $2.0B | ||
| Q1 24 | $360.5M | $2.0B |
总资产PTLORGEN
| Q4 25 | $1.6B | $2.9B | ||
| Q3 25 | $1.6B | $2.9B | ||
| Q2 25 | $1.6B | $2.9B | ||
| Q1 25 | $1.5B | $2.9B | ||
| Q4 24 | $1.5B | $2.8B | ||
| Q3 24 | $1.5B | $2.8B | ||
| Q2 24 | $1.4B | $2.9B | ||
| Q1 24 | $1.4B | $2.8B |
负债/权益比PTLORGEN
| Q4 25 | 0.71× | 0.26× | ||
| Q3 25 | 0.70× | 0.26× | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 0.78× | 0.27× | ||
| Q3 24 | 0.79× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.89× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $23.2M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $-9.2M | $17.6M |
| 自由现金流率自由现金流/营收 | -4.9% | 8.9% |
| 资本支出强度资本支出/营收 | 17.4% | 4.1% |
| 现金转化率经营现金流/净利润 | 3.69× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $-18.5M | $93.9M |
8季度趋势，按日历期对齐
经营现金流PTLORGEN
| Q4 25 | $23.2M | $25.7M | ||
| Q3 25 | $20.0M | $48.1M | ||
| Q2 25 | $19.2M | $28.6M | ||
| Q1 25 | $9.4M | $15.0M | ||
| Q4 24 | $26.1M | $39.2M | ||
| Q3 24 | $30.3M | $49.3M | ||
| Q2 24 | $32.6M | $42.2M | ||
| Q1 24 | $9.1M | $44.7M |
自由现金流PTLORGEN
| Q4 25 | $-9.2M | $17.6M | ||
| Q3 25 | $-5.0M | $43.4M | ||
| Q2 25 | $5.2M | $21.5M | ||
| Q1 25 | $-9.6M | $11.4M | ||
| Q4 24 | $-5.6M | $33.6M | ||
| Q3 24 | $7.7M | $42.3M | ||
| Q2 24 | $15.6M | $37.4M | ||
| Q1 24 | $-7.9M | $36.4M |
自由现金流率PTLORGEN
| Q4 25 | -4.9% | 8.9% | ||
| Q3 25 | -2.7% | 23.0% | ||
| Q2 25 | 2.8% | 11.8% | ||
| Q1 25 | -5.4% | 6.8% | ||
| Q4 24 | -3.0% | 19.3% | ||
| Q3 24 | 4.3% | 27.3% | ||
| Q2 24 | 8.6% | 24.3% | ||
| Q1 24 | -4.7% | 24.0% |
资本支出强度PTLORGEN
| Q4 25 | 17.4% | 4.1% | ||
| Q3 25 | 13.8% | 2.5% | ||
| Q2 25 | 7.5% | 3.9% | ||
| Q1 25 | 10.8% | 2.1% | ||
| Q4 24 | 17.2% | 3.2% | ||
| Q3 24 | 12.7% | 4.5% | ||
| Q2 24 | 9.3% | 3.1% | ||
| Q1 24 | 10.2% | 5.5% |
现金转化率PTLORGEN
| Q4 25 | 3.69× | 1.93× | ||
| Q3 25 | 16.51× | 3.23× | ||
| Q2 25 | 2.21× | 1.92× | ||
| Q1 25 | 2.85× | 2.57× | ||
| Q4 24 | 2.10× | — | ||
| Q3 24 | 4.20× | — | ||
| Q2 24 | 5.03× | 12.70× | ||
| Q1 24 | 1.99× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
